It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff reports that he receives research and grant support from the National Institutes of Health (NIH). He is a consultant for ACADIA Pharmaceuticals Inc.; Bracket (Clintara); EMA Wellness; Gerson Lehrman Group, Inc. (GLG); Intra-Cellular Therapies, Inc.; Janssen Research & Development LLC; Magstim, Inc.; Navitor Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; TC MSO, Inc.; and Xhale, Inc. He holds stock in AbbVie Inc.; Antares Pharma; BI Gen Holdings, Inc.; Celgene Corporation; Corcept Therapeutics; EMA Wellness; OPKO Health Inc.; Seattle Genetics, Inc.; TC MSO, Inc.; Trends in Pharma Development, LLC; and Xhale, Inc. He serves on the board of directors for American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; and Xhale, Inc. He reports other income sources or equity of $10,000 or more from American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; EMA Wellness; Intra-Cellular Therapies, Inc.; Magstim, Inc.; and Xhale, Inc. He holds patents for Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2); Compounds, Compositions, Methods of Synthesis; and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,511,996B2).
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
